Claybrook Capital’s Editas Medicine EDIT Stock Holding History

Claybrook Capital’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4,842	Closed	-$274K	–	158
2021 Q2	$274K	Buy	+4,842	New	+$179K	0.09%	142

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Claybrook Capital's EDIT Position: Q3 2021 in Review

Claybrook Capital sold out of Editas Medicine (EDIT) in Q3 2021, closing a stake of 4,842 shares — an estimated $274K sold.

Claybrook Capital first reported a position in EDIT in Q2 2021 and held it in 1 quarter. The position peaked at $274K in Q2 2021. 318 funds tracked by Wall St. Rank hold EDIT as of Q3 2021.

Claybrook Capital reported no remaining Editas Medicine position as of Q3 2021 after selling out during the quarter.
Claybrook Capital sold 4,842 Editas Medicine shares in Q3 2021, an estimated $274K.
Claybrook Capital first reported a position in Editas Medicine in Q2 2021 and held it in 1 quarter.
Claybrook Capital's Editas Medicine position peaked at $274K in Q2 2021.
318 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2021.

Based on Claybrook Capital's 13F filing for Q3 2021, filed 15 Nov 2021.